A549   HCC2935   H460
H1650   H1299   H522
H596
Calu-3

% proliferation

primary T
Wi-38
TE353.sk

% proliferation

normal cells (BJ)
cancer cells (A549)

% Non-viable cells [vs. miR-NC]

siGAPDH
miR-34a
mock
NT

15 nM  15 nM
30 nM  30 nM
100 nM 100 nM
200 nM 200 nM
Wiggins et al., Supp. Fig. S3

miR-34a  |  miR-NC

Bcl-2
Wiggins et al., Supp. Fig. S4

A

B

miR-34a  vehicle  PBS

H&E  Ki67  Casp

PBS vehicle miR-34a treatment

**  **  *

*  *

n=6  n=5  n=5

n=5  n=5  n=6

15 20 25 30 35 40 45 days

tumor size (mm$^2$)

0 100 200 300 400 500 600 700 800 900
Wiggins et al., Supp. Fig. S5

![Graph showing IL-1β and IL-5 levels over time post-injection for different treatments including miR-34a, miR-NC, vehicle, PBS, and LPS.](image)

- IL-1β [pg/ml]
- IL-5 [pg/ml]
- hours post injection
Wiggins et al., Supp. Fig. S6

![Graph showing fold change of IFIT1 mRNA expression with different treatments.](image-url)